Susquehanna International Group, LLP Keros Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$41.26 - $70.48 $478,616 - $817,568	11,600 New	11,600 $767,000
Q1 2023 May 16, 2023	BUY	$41.44 - $59.32 $256,928 - $367,784	6,200 Added 95.38%	12,700 $542,000
Q4 2022 Feb 14, 2023	SELL	$39.45 - $51.77 $114,405 - $150,133	-2,900 Reduced 30.85%	6,500 $312,000
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $261,320 - $377,128	9,400 New	9,400 $354,000
Q2 2022 Aug 15, 2022	SELL	$26.03 - $67.04 $356,611 - $918,448	-13,700 Closed	0 $0

Q1 2022 May 16, 2022	SELL	$42.12 - $59.36 $1.05 Million - $1.48 Million	-24,900 Reduced 64.51%	13,700 $745,000
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $1.43 Million - $2.43 Million	38,600 New	38,600 $2.26 Million

153

26.7M

47.6K

34.5K

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $1.18B
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.